HDAC9 and mantle cell lymphoma: In this sense, trials conducted by the Nordic group involving more than 160 MCL patients treated with the R-maxi-CHOP/R-HDAC regimen followed by up-front consolidation with ASCT reported an ORR of 96%, with a CR of only 54% for patients not undergoing ASCT and 89% for those who have experienced ASCT.